Key result
A 56-year-old woman with fulminant heart failure due to giant cell myocarditis was successfully treated with ECMO followed by heart transplantation, achieving an LVEF of 60%.
Case Report (n=1)
No
ECMO followed by heart transplantation and immunosuppression can be a successful life-saving strategy for fulminant heart failure due to giant cell myocarditis.
Answers are grounded in this paper and cite their sources.
Supports ECMO-bridge to transplant in fulminant giant cell myocarditis; leaves open generalizability and need for prospective data.
A 56-year-old woman, previously healthy, was hospitalized after an episode of ventricular tachycardia in the course of infection. In view of the fulminant course of heart failure the patient was connected to an extracorporeal membrane oxygenation (ECMO) system. After 3 weeks of treatment with ECMO the patient received a heart transplant. A histopathological examination of the tissues of the explanted heart revealed giant cell myocarditis. The patient was treated with immunosuppression based on induction therapy followed by a standard regimen with steroids. Currently, the patient remains in good general condition with an left ventricular ejection fraction of 60%.
No takes yet. Share an insight, caveat, or question.
Senderek et al. (2015) conducted a case report in Fulminant heart failure due to giant cell myocarditis (n=1). ECMO and heart transplantation was evaluated on Clinical recovery. A 56-year-old woman with fulminant heart failure due to giant cell myocarditis was successfully treated with ECMO followed by heart transplantation, achieving an LVEF of 60%.
Synapse has enriched 10 related papers. Consider them for comparative context: